Figure 1.

6MMPr increases T-1105 antiviral activity against DENV in Huh7 cells. (A) Dose-response curves for reduction of viral titers (red and green lines) and cell viability (blue and purple lines) induced by single treatments of 6MMPr and T-1105. (B) Dose-response curves for reduction of viral titers (red line) and cell viability (blue line) induced by T-1105/6MMPr co-treatment. X axis indicates the different combinations used. The doses for 6MMPr and T-1105 for each combination treatment were 0.08, 0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, and 1.6 times their respective EC₅₀. Data are from three biological replicates. (C) CC₅₀ and EC₅₀ values for 6MMPr, T-1105, and the combination. (D) The bar graph depicts the reduction of viral titer promoted by T-1105/6MMPr co-treatment. X axis represents four different concentrations of T-1105 and the bar color indicates the concentration of 6MMPr. Mean ± SEM of viral titers (PFU/mL) from two independent experiments by duplicates is plotted. (E) 3D plot indicating synergistic antiviral effect. “a”, indicates significant antiviral activity induced by T-1105 alone; *, p < 0.005; ***, p < 0.001; ND, none detected; black dotted line, limit of detection. TVS = total volume of synergy calculated at 99.9% confidence interval.